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Abstract
The Fanconi anaemia (FA) pathway is a dedicated pathway for
the repair of DNA interstrand crosslinks and is additionally acti-
vated in response to other forms of replication stress. A key step
in the FA pathway is the monoubiquitination of each of the two
subunits (FANCI and FANCD2) of the ID2 complex on specific
lysine residues. However, the molecular function of these modifi-
cations has been unknown for nearly two decades. Here, we find
that ubiquitination of FANCD2 acts to increase ID2’s affinity for
double-stranded DNA via promoting a large-scale conformational
change in the complex. The resulting complex encircles DNA, by
forming a secondary “Arm” ID2 interface. Ubiquitination of
FANCI, on the other hand, largely protects the ubiquitin on
FANCD2 from USP1-UAF1 deubiquitination, with key hydrophobic
residues of FANCI’s ubiquitin being important for this protection.
In effect, both of these post-translational modifications func-
tion to stabilize a conformation in which the ID2 complex
encircles DNA.
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Introduction
Repair of DNA damage is an important aspect of cellular biology,
and numerous pathways have evolved to combat different types of
DNA damage [1]. Fanconi anaemia (FA) is a rare genetic disorder
that arises due to mutations within any of the Fanconi anaemia
complementation group (FANC) genes, the products of which are
involved in repair of DNA interstand crosslinks (ICLs) [2,3] as well
as in the maintenance of genomic stability in response to replication
stress [4,5]. While quite rare in the general population, FA pathway
genes are frequently altered in cancer patients [3].
A key step in this pathway is the ubiquitination of a pair of paral-
ogous proteins, FANCI (~ 150 kDa) and FANCD2 (~160 kDa) [6,7],
which promotes their retention on chromatin [7,8]. In particular,
ubiquitination of FANCD2 has been shown to be indispensable for
cellular resistance to mitomycin C [6,9], which promotes ICLs.
Unlike typical ubiquitination events, FANCI and FANCD2 are each
specifically monoubiquitinated at a single conserved lysine. Ube2T-
FANCL are the E2–E3 pair that mediate ubiquitination [10,11]. In
many eukaryotes, including humans, FANCL is incorporated into a
pseudo-dimeric ~ 1 MDa complex which is known as the FA core
complex [12,13, preprint: 14]. Removal of the ubiquitins, on FANCI
and FANCD2, is also critical for the FA pathway, and this deubiqui-
tination step is catalysed by the USP1-UAF1 complex [15,16].
Evidence suggests FANCI and FANCD2 are involved in recruit-
ment of other proteins [8,17]. However, the mechanistic and struc-
tural details of the role of ubiquitination remain ambiguous. The
two proteins have been shown to associate in vivo [7] and form a
heterodimer in vitro [18]. A crystal structure of the non-ubiquiti-
nated mouse FANCI-FANCD2 (ID2) complex revealed that each
paralog has an extensive a-solenoid fold contorted into a saxo-
phone-like shape [18]. Interestingly, the ubiquitination target lysines
are partially buried at the FANCI-FANCD2 interface, which extends
throughout the N-terminal halves of the proteins. It has been
suggested that the ubiquitin conjugated on FANCI interacts with
FANCD2 [19]. The presence of DNA promotes ubiquitination of
both isolated FANCI and ID2 complex in vitro [20,21], but it is
currently unknown how this is achieved. While isolated FANCI and
ID2 complex are well known to bind various DNA structures
[18,20–23], isolated FANCD2 is less well established to bind DNA
[18,22,24]. A FA patient mutation in FANCI, R1285Q, which reduces
ubiquitination of the ID2 complex [20,21], has been suggested to
reduce both FANCI and ID2 DNA binding, as well as FANCI interac-
tion with FANCD2; however, the magnitude of reduction in DNA
binding contrasts between the studies [20–22].
Although FANCD2 monoubiquitination has been documented for
almost two decades [6] and FANCI monoubiquitination for over one
decade [7], the molecular function of these modifications has been
elusive. This has been largely due to the difficulty in isolating pure
monoubiquitinated FANCI and FANCD2 proteins for in vitro studies.
Recent advances in the understanding of the Ube2T allosteric
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activation by FANCL have allowed for the development of an engi-
neered Ube2T which retains FANCI/FANCD2 lysine specificity but
displays enhanced monoubiquitination activity [25]. This engi-
neered Ube2T has facilitated preparation and isolation of highly
purified ubiquitinated FANCI and FANCD2 without the need of
DNA [26]. Here, we have used this approach to reconstitute the
human ID2 complex in different states of ubiquitination and have
characterized DNA binding for each state. We show that ubiquitina-
tion of FANCD2 significantly enhances binding of the ID2 complex
to dsDNA, while ubiquitination of FANCI appears to be dispensable
for this purpose. CryoEM maps of ubiquitinated FANCD2 in
complex with either FANCI, or ubiquitinated FANCI and dsDNA,
demonstrate a closure of the ID2 complex via formation of a new
protein–protein interface at the C-termini. This interface is appar-
ently disrupted in the FANCI R1285Q pathogenic mutant. We further
demonstrate that ubiquitination of FANCI largely protects the ID2
complex from USP1-UAF1 deubiquitination, which likely contri-
butes to the maintenance of ubiquitination-associated ID2-DNA
binding enhancement in the cellular context. Therefore, it appears
that ubiquitination of FANCI and FANCD2 have separate functions
but converge to facilitate and maintain improved ID2-DNA binding.
Results and Discussion
Ubiquitination of FANCD2 enhances ID2-dsDNA binding
In order to explore whether FANCI and FANCD2 ubiquitination
impacts ID2-DNA binding, we first ubiquitinated and purified human
FANCI (IUb) and FANCD2 (D2Ub) separately using our previously
established protocol, which does not require the use of DNA [25,26].
We then reconstituted the non-ubiquitinated ID2 complex (I + D2), the
ID2Ub complex, with ubiquitin only on FANCD2 (I + D2Ub), and the
IUbD2Ub complex, with ubiquitin on both FANCI and FANCD2
(IUb + D2Ub). We employed both solution-based protein-induced fluo-
rescence enhancement (PIFE; 22°C) [27] and gel-based electro-mobility
shift assays (EMSAs; 4°C) to assess dsDNA binding to the above
complexes (32 base pair, IRDye700 labelled; Figs 1 and EV1). The two
techniques revealed a striking enhancement of DNA binding when
FANCD2 was ubiquitinated (ID2Ub) compared to the unmodified
complex (ID2). However, we observed that ID2 and ID2Ub DNA bind-
ing in PIFE experiments was highly sensitive to salt concentration
(Fig EV1A), as expected for DNA–protein interactions. In contrast,
corresponding dissociation constants determined by EMSA were only
modestly affected due to salt changes and were significantly lower than
PIFE (Fig EV1B). We reasoned that the above were due to protein–
DNA samples entering a virtually salt-free gel environment (0.5× TBE)
in the case of EMSA and hence this technique may not result in dissoci-
ation constants that reflect the salt environment where binding takes
place. Thus, we determined apparent dissociation constants at physio-
logical NaCl concentrations (150 mM) using PIFE (Fig 1A).
A ~ 10-fold enhancement of DNA binding affinity was observed
for ID2Ub compared to ID2 (Fig 1A). DNA binding was not detect-
able under similar concentrations of isolated D2Ub, suggesting that
the ubiquitin on FANCD2 is not required for DNA binding per se,
but enables a stronger ID2-DNA interaction. Interestingly, the di-
monoubiquitinated complex (IUbD2Ub) did not have a significantly
different dsDNA binding affinity compared to ID2Ub (Fig 1A).
Similarly, EMSAs of reconstituted complexes also showed that ID2Ub
and IUbD2Ub binding to dsDNA was comparable, and enhanced rela-
tive to ID2, whereas D2Ub showed no DNA binding (Fig 1B). These
data suggest that FANCD2 ubiquitination serves to either promote
or stabilize ID2-DNA binding and are consistent with associated
increases in ID2-DNA binding upon FANCD2 ubiquitination
reported in three recent EMSA-based studies [28–30].
Ubiquitination of FANCD2 is associated with formation of a
secondary ID2 interface
To examine the structural details of enhanced DNA binding affinity,
we determined cryoEM maps of reconstituted human ID2 complexes
with ubiquitinated FANCD2, at modest resolutions (Figs 2A and
A
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Figure 1. FANCD2 ubiquitination enhances ID2-dsDNA binding.
IRDye700-labelled 32 base pair dsDNA was used to assess ID2-DNA binding,
when neither protein is ubiquitinated (I + D2), when only FANCD2 is
ubiquitinated (I + D2Ub) and when both FANCD2 and FANCI are ubiquitinated
(IUb +D2Ub).
A Left: Fluorescence changes of IRDye700-labelled dsDNA (at 125 nM) when
incubated at increasing ID2 (I + D2, IUb + D2Ub, I + D2Ub) or ubiquitinated
FANCD2 (D2Ub) concentrations (ranging from 1.3 nM to 5.9 lM).
Measurement of fluorescence enhancement for each ID2 complex was
conducted for two separately prepared complexes (two technical repeats)
and all data points for each protein combination were used in fitting of a
one-site binding model. Right: Bar graph showing mean apparent Kd values
calculated from model fitting. Error bars: Asymmetric 95% confidence
intervals from non-linear regression (23–24 data points each).
B Assessment of protein–DNA interactions using electro-mobility shift assays
(EMSAs). IRDye700-labelled dsDNA (at 2 nM) was incubated with indicated
amounts of non/single/double-ubiquitinated ID2 (His6-TEV-V5-FANCI and
FLAG-FANCD2) protein complexes (I + D2, IUb + D2Ub, I + D2Ub) or
ubiquitinated FLAG-FANCD2 (D2Ub). Mixes were run on non-denaturing
gels, and the resolved free- and protein-bound DNA bands were visualized
using an infrared scanner. EMSA gels of ID2 complexes are representative of
3 replicate experiments.
Source data are available online for this figure.
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EV2). Reference-free 2D class averages of ID2Ub and IUbD2Ub-dsDNA
exhibited similar overall shapes, but different to previous non-
ubiquitinated ID2 class averages [12], hinting at a gross conforma-
tional change upon ubiquitination of FANCD2. Reconstructed maps
of ID2Ub and IUbD2Ub-dsDNA, at resolutions of 24 and 12 Å, respec-
tively, both exhibited a closed, torus-like shape. Fitting of the mouse
truncated ID2 crystal structure (3S4W) into the IUbD2Ub-dsDNA map
resulted in a poor fit (Fig 2B; left panel), but flexible fitting using
iMODFIT [31] with secondary structure restraints improved the
agreement (cross-correlation score from 0.56 to 0.85). The primary
movement occurred for the FANCD2 C-terminal “arm” and resulted
in formation of a new interface with the FANCI C-terminal “arm”
that closes the ID2 complex (Fig 2B; right panel). We refer to this
interface henceforth as the Arm ID2 interface. A difference map
between the fitted model and the experimental map illustrates a
tube-like volume, most likely representing the bound DNA. This
volume is positioned just below the Arm ID2 interface and encom-
passed within the torus (Fig 2B; right panel), suggesting that forma-
tion of the Arm ID2 interface is necessary for this binding
conformation. At these resolutions, we are not able to unambigu-
ously place the conjugated ubiquitins. We propose that the closed
conformation must be stabilized to tightly bind DNA and ubiquitina-
tion of FANCD2 acts for this purpose. The closed conformation is
consistent with recent cryoEM structures of DNA-bound human
ID2Ub and IUbD2Ub [28], and chicken ID2Ub [29].
The Arm ID2 interface is required for enhanced
ID2-dsDNA binding
Interestingly, the site of the pathogenic FANCI mutation R1285Q is
in proximity to the Arm ID2 interface (Fig 3A) and in the recent
atomic model of human IUbD2Ub forms a salt bridge with Q1365 on
FANCD2 [28]. We hypothesized that this mutation may disturb ID2
ubiquitination by reducing formation of the closed ID2 state. We
first examined whether this mutation brings any changes in FANCI’s
capacity to interact with DNA and FANCD2, as well as whether it
affects FANCI’s ability to get ubiquitinated. We found that both
wild-type (IWT) and mutant (IR1285Q) proteins could be ubiquitinated
in vitro to the same extent, and addition of DNA resulted in compa-
rable enhancement of ubiquitination between the two proteins
(Fig 3B). Furthermore, by measuring the binding affinities of RED-
tris-NTA (NanoTemper) labelled His-tagged IWT and IR1285Q for
FANCD2 (using PIFE), we found that the affinities were similar and
both in the low nanomolar range (Fig 3C). Nevertheless, the FANCI
mutation resulted in an apparent reduction in FANCD2 ubiquitina-
tion in the ID2 complex (Fig 3D), consistent with previous results
[20,21,28]. Under our assay conditions, we did not detect a signifi-
cant change in FANCI ubiquitination in the ID2 complex due to the
mutation. Nevertheless, the FANCI R1285Q mutation was recently
shown to result, not only in a reduction of FA core catalysed FANCI
and FANCD2 ubiquitination within an ID2 complex [preprint: 14],
but also in faster deubiquitination of the ubiquitinated complex
[28]. This slower ubiquitination and faster deubiquitination may
explain the nearly complete absence of ubiquitinated FANCD2/
FANCI seen in cells having the FANCI R1285Q mutation [7].
Interestingly, the reconstituted mutant IR1285QD2Ub complex
behaved differently in terms of dsDNA binding enhancement,
compared to the wild-type ID2Ub complex. PIFE revealed only a
minor, insignificant reduction of ID2-DNA affinity when FANCI was
mutated to FANCIR1285Q, and when FANCD2 was ubiquitinated the
ID2-DNA affinity was not substantially enhanced, unlike that seen
for wild-type complex (Fig 3E). EMSAs similarly showed a small
increase in IR1285QD2-DNA binding when FANCD2 was ubiquiti-
nated (Fig 3F), unlike the levels observed with IWTD2 versus
IWTD2Ub. Taken together, these results suggest that the FANCI
R1285Q
patient mutation does not directly alter ID2-dsDNA binding, but
instead restricts FANCD2 ubiquitination and the associated DNA
binding enhancement. This is likely achieved via disruption of the
Arm ID2 interface, seen in the closed ID2 state. Hence, the loss of
FANCD2 ubiquitination in IR1285QD2 complex can be rationalized if
the closed state is also important for its ubiquitination.
FANCI ubiquitination protects ID2Ub complex against
USP1-UAF1 deubiquitination
The USP1-UAF1 complex specifically targets ubiquitinated FANCD2
for deubiquitination utilizing an N-terminal module of USP1 [32].
Although this can occur when D2Ub is in isolation or in complex
with FANCI, di-monoubiquitinated ID2 complexes (IUbD2Ub) bound
to DNA remain largely resistant to USP1-UAF1 deubiquitination
[32,33]. We hypothesized that since FANCI ubiquitination does not
further enhance ID2-DNA binding, its primary role may be in
protecting FANCD2’s ubiquitin from USP1-UAF1 activity. To exam-
ine to what extent the presence of I or IUb influences D2Ub deubiq-
uitination, we compared the progress of D2Ub, ID2Ub and IUbD2Ub
deubiquitination by USP1-UAF1 (in the presence of dsDNA) in a
time course (Fig 4A). USP1-UAF1, at low (25 nM) concentrations,
deubiquitinated both D2Ub and ID2Ub at similar rates. However,
the IUbD2Ub substrate remained almost completely resistant to
USP1-UAF1 activity (Fig 4A; Left). At higher concentrations of
USP1-UAF1 (100 nM), we found that FANCD2 can be deubiquiti-
nated, albeit at slower rate than D2Ub and ID2Ub, which are rapidly
deubiquitinated in under 10 min (Fig 4A; Right). These data
suggest that access to the ubiquitin on FANCD2 for USP1-UAF1 is
reduced when in complex with ubiquitinated FANCI and DNA. In
vitro [25,33] and cell-based [7] assays have shown that the block-
age of FANCI ubiquitination also results in reduced FANCD2 ubiq-
uitination. According to our data, this may occur because
FANCD2’s ubiquitin is no longer sufficiently protected against
USP1-UAF1 deubiquitination.
Since USP1-UAF1 is a specific deubiquitinase (DUB) for FANCD2
[15,32], we wanted to assess whether alternative DUBs, that lack
FANCD2 specificity (i.e. target structurally diverse substrates), are
also able to access the ubiquitin on FANCD2 when this is in
complex with I or IUb. We therefore assayed deubiquitination of
D2Ub, ID2Ub and IUbD2Ub by USP7 and USP2 (in the presence of
dsDNA) in a time course (Fig 4B). While USP7 and USP2 could
deubiquitinate D2Ub in isolation, the presence of FANCI or ubiquiti-
nated FANCI reduced D2Ub deubiquitination. This result suggests
that, in the ID2Ub-DNA and IUbD2Ub-DNA complexes, the ubiquitin
on FANCD2 is protected against generic DUB activity. A potential
explanation for the protection is that FANCI may block DUB access
by interacting with FANCD2’s ubiquitin. Indeed, recently reported
ID2Ub-DNA structures show that FANCD2’s ubiquitin directly inter-
acts with FANCI [28,29]. However, USP1-UAF1 is apparently able to
circumvent any protection formed from a locked ID2Ub-DNA
ª 2020 The Authors EMBO reports 21: e50133 | 2020 3 of 13
Martin L Rennie et al EMBO reports
complex. These data suggest that USP1-UAF1 may be capable of
modulating the ID2Ub-DNA complex in order to gain access to
FANCD2’s conjugated ubiquitin. Although the exact details by
which this is achieved are not known, our recent work has shown
that a FANCD2-binding sequence, located at USP1’s N-terminus, is
required for efficient ID2Ub-DNA deubiquitination [32]. Neverthe-
less, our work here shows that this ability of USP1-UAF1 is compro-
mised when FANCI is also ubiquitinated. The effect of FANCI’s
ubiquitination may be on rendering the doubly ubiquitinated ID2
complex unamenable to USP1-UAF1 modulation, for example by
stabilizing an ID2 conformational change induced by FANCD2 ubiq-
uitination or inducing further minor conformational changes that
stabilize the complex. Alternatively, FANCI ubiquitination may
directly disrupt USP1-UAF1 binding to FANCD2.
One explanation for FANCI’s conjugated ubiquitin facilitating a
USP1-UAF1 resistant complex is that this ubiquitin interacts with
FANCD2. Ubiquitin typically interacts with other proteins via any of
its three (F4, I36 and I44) hydrophobic patches [34]. Thus, we
mutated four key hydrophobic residues of ubiquitin located within
these patches, which are at distinct regions of the ubiquitin structure
(Fig 4C). Subsequently, we ubiquitinated FANCI (in the presence
dsDNA) using either wild-type or one of these four ubiquitin
mutants (F4A, I36A, L73A or I44A). Nearly complete FANCI ubiqui-
tination was achieved for each mutant and wild-type ubiquitin
(Fig 4D). We tested each IUb in DUB assays and found that only IUb-
I44A was also deubiquitinated to the same extent as IUb-WT by USP1-
UAF1. The I36A mutation resulted in partial loss, whereas the F4A
and L73A mutations on ubiquitin resulted in complete loss of USP1-
A
B
Figure 2. FANCD2 ubiquitination creates a secondary ID2 “Arm” interface, resulting in a closed ID2 conformation.
A Left: CryoEM 2D classes of ID2Ub and IUbD2Ub-dsDNA. Right: 3D reconstructions of ID2Ub (EMD-10843) and IUbD2Ub-DNA (EMD-10844). Both structures exhibit a
torus-like shape.
B Left: Rigid body fit of the mouse ID2 atomic structure (3S4W) into the human IUbD2Ub-dsDNA cryoEM map. Right: Flexible fit of the mouse ID2 atomic model into the
human IUbD2Ub-dsDNA cryoEM map (iMODFIT). The C-termini “arms” of FANCD2 and FANCI close in the flexible fitting. A tube-like volume in the IUbD2Ub-DNA
cryoEM map, which is not occupied by the ID2 iMODFIT structure, is present just beneath the Arm ID2 interface and likely represents bound DNA (solid density).
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UAF1 activity (Fig 4D). To assemble IUbD2Ub-DNA complex with
ubiquitin mutants on FANCI, we added D2Ub to each ubiquitin-
mutated IUb and subjected the resulting IUbD2Ub-DNA complex to
deubiquitination treatment with USP1-UAF1 (Fig 4E). Both F4A and
I44A ubiquitin mutations, despite having contrasting effects on
deubiquitination of FANCI alone, resulted in an increased suscepti-
bility to FANCD2 deubiquitination. The I36A and L73A mutations
had negligible effects on FANCD2 deubiquitination (Fig 4E). The
same effect of I44A and F4A on FANCD2 deubiquitination was
observed when using four times lower concentrations of USP1-
UAF1 in single time-point DUB assays (Fig EV3A). We reasoned that
ID2-DNA binding or complex formation was unaffected by these
mutations, since WT, F4A and I44A IUbD2Ub complexes were still
able to bind DNA efficiently, unlike IUb alone (Fig EV3B) or D2Ub
A
D
F
E
B C
Figure 3. The pathological FANCI R1285Q mutation disrupts ID2 ubiquitination, likely via disturbing the closed ID2 conformation.
A Arginine 1285 of FANCI, which is mutated in some FA patients, is located in the Arm ID2 interface in our cryoEM IUbD2Ub-dsDNA structure.
B Both wild-type (IWT) and R1285Q mutant (IR1285Q) FANCI can be efficiently ubiquitinated in the presence of DNA. Reactions were performed at 2 lM FANCI substrate
for 60 min in the absence or presence of 4 lM ssDNA.
C Both wild-type (IWT) and R1285Q mutant (IR1285Q) FANCI efficiently associate with FANCD2. Fluorescence changes occurring when RED-tris-NTA-labelled FANCI (IWT or
IR1285Q; both at 60 nM) is incubated at increasing concentrations of FANCD2 (ranging from 2.48 nM to 5.08 lM). Titrations were conducted twice (two technical
replicates), and all data points for each protein combination were used in fitting of a one-site binding model. Apparent Kd values (mean  SEM) derived from fitting
of a one-site binding model to the 24 data points of the two technical replicates are shown.
D FANCD2 within an IR1285QD2 complex is resistant to ubiquitination. Reactions were performed at 4 lM ID2 substrate and 16 lM dsDNA. Progress of FANCD2 and
FANCI ubiquitination was monitored by Western blotting following SDS–PAGE.
E FANCD2 ubiquitination cannot robustly enhance ID2-DNA binding when complexed with IR1285Q, as determined by PIFE. Left: Fluorescence changes when IRDye700-
labelled dsDNA (at 125 nM) is incubated at increasing concentrations of IR1285Q + D2 or IR1285Q + D2Ub (complex concentrations ranging from 1.54 nM to 3.8 lM).
Measurement of fluorescence enhancement for each protein combination was conducted for two separately prepared complexes (two technical repeats), and all data
points for each protein combination were used in fitting of a one-site binding model. Right: Bar graph showing mean apparent Kd values calculated from the one-site
binding model. Error bars: Asymmetric 95% confidence intervals from non-linear regression (22 data points each). IWT + D2 and IWT + D2Ub previously calculated
curves and corresponding Kd values (from data points shown in Fig 1A) are also shown for comparison.
F FANCD2 ubiquitination cannot robustly enhance ID2-DNA binding when complexed with IR1285Q, as determined by EMSAs. IRDye700-labelled dsDNA (at 2 nM) was
incubated with indicated amounts of ID2 (His6-FANCI or His6-FANCI
R1285Q) mixed with non-ubiquitinated or ubiquitinated FLAG-FANCD2. Mixes were run on non-
denaturing gels, and the resolved free- and protein-bound DNA bands were visualized using an infrared scanner. Gels shown are representative of two replicate
experiments.
Source data are available online for this figure.
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Figure 4. FANCI ubiquitination of ID2Ub protects D2Ub from USP1-UAF1-mediated deubiquitination.
A USP1-UAF1 can efficiently deubiquitinate D2Ub in the presence or absence of FANCI (I), but not in the presence of ubiquitinated FANCI (IUb). Ubiquitinated FANCD2
(D2Ub) was mixed with a 50 base pair dsDNA and either His6-TEV-V5-FANCI (I), ubiquitinated His6-TEV-V5-FANCI (IUb) or no protein; protein–DNA mixes were
subsequently incubated with USP1-UAF1 (at 25 nM or 100 nM) for indicated time periods. Deubiquitination of D2Ub and IUb was assessed, following SDS–PAGE, by
Coomassie staining of the gels, as well as by Western blotting of transferred blots with a specific FANCD2 antibody.
B USP7 and USP2 can deubiquitinate D2Ub, but their activity towards D2Ub is greatly reduced in the presence of FANCI (I) or ubiquitinated FANCI (IUb). Reactions were
set up as in (A), but with 100 nM USP7 or USP2. Deubiquitination was assessed, following SDS–PAGE, by Coomassie staining.
C Location of the four hydrophobic residues mutated to alanine in the ubiquitin structure (PDB: 1ubq). Top: location of F4, I36, I44 and L73 (shown in red) in ubiquitin’s
surface (shown in yellow). Bottom: same as above but with ubiquitin’s surface coloured according to charge (red: negative, blue: positive, white: no charge).
D Time course of FANCI ubiquitination with various ubiquitin mutants and corresponding sensitivity/resistance to USP1-UAF1-mediated deubiquitination of resulting
products. Deubiquitination reactions in the presence or absence of USP1-UAF1 (100 nM) incubated for 30 min.
E Time course of USP1-UAF1-mediated deubiquitination of IUbD2Ub-DNA complexes consisting of D2Ub a 50 base pair dsDNA and IUb produced with various ubiquitin
mutants or wild-type (WT) ubiquitin. Progress of deubiquitination reaction was assessed following SDS–PAGE, by both Coomassie staining of the gels and Western
blotting of transferred blots with a specific FANCD2 antibody. FANCI ubiquitination with indicated ubiquitin mutants (or WT) and subsequent deubiquitination of
resulting IUbD2Ub-DNA complexes were conducted twice; the residual FANCD2 ubiquitination, calculated from the FANCD2 blots for each time-point, was plotted for
each type of ubiquitin in the protein complex, and corresponding deubiquitination progress curves were fitted using a one-phase decay model.
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alone (Fig 1). Taken together, these data suggest the F4 and I44
hydrophobic surfaces on ubiquitin are important for IUb-mediated
protection of D2Ub, potentially via interaction with FANCD2. Indeed,
in the recently reported IUbD2Ub-DNA structure [28], I44 of FANCI’s
conjugated ubiquitin is located within the FANCD2–ubiquitin inter-
face. In contrast, F4 does not appear to directly contact FANCD2 in
this structure. Hence, the F4A mutation may instead favour
FANCD2 deubiquitination either by disturbing FANCI deubiquitina-
tion (Fig 4D), or via changing ubiquitin dynamics [35], thus altering
the ubiquitin–FANCD2 interface.
Interestingly, the ubiquitin on FANCI was also protected from
USP2, USP7 and USP1-UAF1 deubiquitination in the IUbD2Ub-DNA
complex. In fact, in the context of the IUbD2Ub-DNA complex, FANCI
deubiquitination was far from complete at 40 min, even at the high-
est USP1-UAF1 concentration used (Fig EV4). However, isolated IUb
was completely deubiquitinated within 30 min by USP1-UAF1
(Fig 4D). Moreover, we observed that FANCD2 was deubiquitinated
by USP1-UAF1 faster than FANCI in the IUbD2Ub complex (Fig EV4).
This observation implies that an ordered deubiquitination mecha-
nism may be in place, resulting in an IUbD2 complex intermediate.
Our reconstitution approach allowed us to test the DNA binding
affinity of this complex, which was found to be intermediate, i.e.
tighter than that of ID2 but weaker than that of IUbD2Ub (Fig EV5).
Hence, if such a complex results from USP1-UAF1 deubiquitination,
it is likely to retain a certain extent of the strong association with
DNA observed with IUbD2Ub, potentially via partially stabilizing the
closed state.
Taken together, our results suggest that the sequential action of
FANCD2 and FANCI ubiquitination results in a stable IUbD2Ub-DNA
complex, resistant to deubiquitination. The deubiquitination resis-
tance of this complex likely serves to increase the in vivo half-life of
the closed ID2 complex. In that way, a threshold event is created
whereby once two ubiquitins are installed on the ID2 complex the
latter is committed for its function. In contrast, the intermediate
ID2Ub complex is transient and rapidly deubiquitinated.
Previous work has shown that when DNA is removed from the
reaction, di-monoubiquitinated ID2 is no longer resistant to deubiq-
uitination by USP1-UAF1 [32,33], but it is currently not clear how
DNA may protect IUbD2Ub from USP1-UAF1 deubiquitination. One
possibility is that in the absence of DNA ubiquitinated FANCD2
dissociates from ubiquitinated FANCI, and in isolation both proteins
are known to be susceptible to USP1-UAF1 activity [32]. However,
the effect of DNA binding on the strength of interaction between
FANCI and FANCD2 in different ubiquitination states is unknown
and will require description beyond 1:1 binding models. Neverthe-
less, removing DNA might be an effective way of achieving rapid
ID2 deubiquitination and switching off the pathway. This could be
achieved in a cellular context by extraction of ubiquitinated ID2
complexes by the DVC1-p97 segregase [36] and subsequent deubiq-
uitination by USP1-UAF1. Future work will be required to under-
stand the sequence of events, DNA dependence and when other
factors are involved in IUbD2Ub deubiquitination.
The combined action of FANCD2 and FANCI ubiquitination
stabilizes ID2 on DNA
Our above results demonstrate separate functions for the two
monoubiquitination events occurring on the ID2 complex. FANCD2
ubiquitination was found to modulate ID2-dsDNA binding affinity,
whereas FANCI ubiquitination was found to largely protect the ubiq-
uitinated ID2 complex from deubiquitination. A simple explanation
for our data is that the ID2 complex can explore two different
conformational extremes: an open state, as in the previously
reported non-ubiquitinated ID2 crystal structure and EM maps
[12,18,37], and a closed state, as observed here (Fig 5). We propose
that DNA binding allows a population of ID2 to reach the closed ID2
conformation, in which the Arm ID2 interface forms. This conforma-
tional change likely exposes FANCD2’s target lysine, as well as its
adjacent acidic patch [25] to allow docking of Ube2T and subse-
quent FANCD2 ubiquitination, which stabilizes the closed state.
However, the action of USP1-UAF1 within the cell will allow a popu-
lation of ID2Ub to revert to an open state via the unstable closed
state of deubiquitinated ID2. The sequential ubiquitination of FANCI
may ensure that the majority of the ID2 population exists in the
closed state, since IUbD2Ub is largely protected from USP1-UAF1
activity. Hence, FANCD2 ubiquitination appears to enhance ID2-
DNA binding by reaching the closed state, while FANCI ubiquitina-
tion acts to maintain this closed state (and thus the higher DNA
affinity), by impairing deubiquitination. As a result, the sequential
action of FANCD2 and FANCI ubiquitination is expected to lock the
ID2 complex on DNA. Since FANCI’s Arginine 1285 is located near
the observed Arm ID2 interface in our cryoEM structures, the
R1285Q mutation on FANCI is expected to disturb this interface by
inhibiting the closed ID2 state and subsequent ubiquitination events
that depend on this (Fig 5). Indeed, R1285 of FANCI, although
unstructured in non-ubiquitinated ID2, was recently shown to
form a salt bridge with E1365 of FANCD2 in an IUbD2Ub-DNA
structure [28].
Our model suggests a sequence of events, where a FANCD2 ubiq-
uitination is first required to achieve a shift towards an ID2 state
with higher DNA affinity and then FANCI ubiquitination follows to
maintain this state. This is consistent with the observations that
FANCI ubiquitination lags behind FANCD2 ubiquitination in vitro
[25,33]. Although we cannot exclude the possibility of an IUbD2
complex population existing in vivo, such a population is more
likely to arise from IUbD2Ub deubiquitination (Fig EV4). The IUbD2
complex apparently has partially enhanced ID2-DNA affinity, and in
light of the recent ID2 and IUbD2Ub structures where the ubiquitin
on FANCI clashes with FANCD2 in the unmodified state [28], there
are likely to be some structural changes associated with IUbD2
complex compared to ID2.
It is possible that ubiquitination-dependent locking of ID2 on
DNA ensures that the complex is properly recruited to sites of repli-
cation arrest where it may be needed. As such, our data are consis-
tent with the observed enrichment of ubiquitinated forms of
FAND2/FANCI in chromatin [7,8]. DNA-bound ID2Ub or IUbD2Ub
complexes may be able to slide, recognize a specific DNA structure
or execute another unknown function, which will result in the
concentrated ID2 foci frequently observed in nuclei of DNA-
damaged cells [7]. Recent reports indicate that IUbD2Ub is able to
slide on circular DNA, since it dissociates from this much slower
than linear DNA [28], and its association with dsDNA may result in
filament-like structures [30].
Future work should seek to further validate the conformational
changes driven by FANCI/FANCD2 ubiquitination in solution and
the role of DNA in these changes. For example, SAXS measurements
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of the different ubiquitination states could be compared. FRET
measurements with FANCI and FANCD2, labelled near the C-
termini, may be able to reveal the population of open and closed
conformation for each ubiquitination state and how these popula-
tions are affected by DNA binding. In addition, cell-based experi-
ments may be used to test the individual function of FANCI and
FANCD2 ubiquitination in vivo. For example, regarding FANCD2
ubiquitination, the extent of ID2 chromatin association or foci
formation could be assessed in cells where FANCI cannot be ubiqui-
tinated and USP1-UAF1 is additionally defective.
Here, we have uncovered distinct functions for two specific
monoubiquitination events on FANCI and FANCD2 within the ID2
complex. We find that FANCD2 ubiquitination enhances binding of
the ID2 complex to dsDNA, while FANCI ubiquitination protects the
complex from deubiquitination by USP1-UAF1. Combined, both
events lead to a stable ID2 complex on dsDNA.
Materials and Methods
Cloning and mutagenesis of expression constructs
Constructs encoding for human FANCD2 having an N-terminal 3C-
cleavable His6-tag (His6-3C-FANCD2), and human FANCI having N-
terminal His6 and V5 tags separated by a TEV-cleavable site (His6-
TEV-V5-FANCI), were described previously [26]. Related FANCD2
and FANCI constructs encoding for a His6-3C-FLAG-tagged FANCD2
or His6-FANCI proteins were produced by site-directed mutagenesis.
The R1285Q mutation was introduced into His6-FANCI by site-
directed mutagenesis in the respective FANCI construct. Human
USP7 was ligated into a pFBDM vector by restriction cloning to
encode for His6-3C-USP7. N-terminally His6-TEV-tagged USP1 (with
G670A/G671A mutated auto-cleavage site [38]) and UAF1 were
produced via sequential insertion of human USP1 and UAF1 cDNAs
Figure 5. Model of how di-monoubiquitination may shift the ID2 conformation to an enhanced DNA-binding state.
ID2 interaction with DNA is proposed to promote a dynamic equilibrium where ID2 can exist in both an open and a closed conformation. FANCD2 ubiquitination by Ube2T
and the FA core complex, within a closed ID2 conformation status, can shift this equilibrium in favour of the closed conformation, with the action of USP1-UAF1
counteracting such shift. When FANCI is also ubiquitinated by Ube2T and the FA core complex, both ubiquitins are largely resistant to USP1-UAF1 deubiquitination, and thus,
the doubly ubiquitinated ID2 can remain in the closed conformation. The latter conformation has a tighter DNA affinity and hence locks ID2 onto DNA. The R1285Qmutation
on FANCI likely restricts formation of a closed ID2 conformation, which in turn negatively impacts on ID2 ubiquitination and locking onto DNA.
8 of 13 EMBO reports 21: e50133 | 2020 ª 2020 The Authors
EMBO reports Martin L Rennie et al
into an appropriate pFBDM vector by restriction cloning. All other
constructs have been reported previously [25,26,32]. The coding
regions of all constructs were verified by DNA sequencing.
Protein expression and purification
All FANCI and FANCD2 constructs were expressed in Sf21 insect
cells, lysed by sonication in the presence of benzonase and purified
by Ni-NTA affinity chromatography, anion exchange and gel filtra-
tion as previously described [26]. In some cases, the His6-tag was
removed from His6-3C-FANCD2 or His6-3C-FLAG-FANCD2 by 3C
protease cleavage, prior to the gel filtration step. Ubiquitinated
FANCI and FANCD2 were produced and purified following in vitro
reactions with Spy-3C-tagged ubiquitin, covalent linkage of ubiquiti-
nated proteins with GST-tagged SpyCatcher, capture of resulting
products on glutathione beads and subsequent cleavage of ubiquiti-
nated proteins by 3C-protease treatment, as described previously
[26]. For ubiquitinated His6-TEV-V5-FANCI and FLAG-FANCD2
used in EMSAs, the steps including the reaction with Spy-3C-tagged
ubiquitin and subsequent covalent linkage of ubiquitinated proteins
with GST-SpyCatcher were instead replaced by reactions with GST-
3C-tagged ubiquitin. The 3C-protease treatment of ubiquitinated
FANCD2 also resulted in removal of the six-histidine-tag from ubiq-
uitinated FANCD2 constructs. After the final gel filtration step, puri-
fied proteins in GF buffer (20 mM Tris pH 8.0, 400 mM NaCl, 5%
glycerol, 5 mM DTT or 0.5 mM TCEP) were cryo-cooled in liquid
nitrogen in single use aliquots. The His6-FANCI R1285Q mutant was
expressed and purified in the same way as the wild-type one.
Preparation of bacmids and protein expression in Sf21 insect cells
for USP1-UAF1 and USP7 was performed as previously described for
FANCI and FANCD2 [26]. All steps following cell harvesting and
prior to protein storage were performed at 4°C. Cells were harvested
~ 72 h following baculovirus infection. Cells were pelleted by
centrifugation, and cell pellets were resuspended in fresh ice-cold
lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5% glycerol, 5 mM
b-mercaptoethanol, 10 mM imidazole, EDTA-free protease inhibitor
cocktail (Pierce), 2 mM MgCl2 and benzonase). Cells were lysed by
sonication and clarified (32,000 × g for 45 min) before proteins
were bound to Ni-NTA resin. Ni-NTA-bound His6-TEV-tagged USP1-
UAF1 complex and His6-3C-tagged USP7 were further washed with
50 mM Tris pH 8.0, 150 mM NaCl, 5% glycerol, 1 mM TCEP and
10 mM imidazole and then eluted into low salt buffer (50 mM Tris
pH 8.0, 100 mM NaCl, 5% glycerol, 1 mM TCEP) containing
250 mM imidazole. Anion exchange was performed for both USP1-
UAF1 and USP7 by binding proteins to a ResourceQ (1 ml) column
and eluting over a linear gradient (20 column volumes) of NaCl
(100–1,000 mM) in 20 mM Tris pH 8.0, 5% glycerol and 1 mM
TCEP. Fractions containing USP1-UAF1 were subject to His-TEV
protease overnight (ratio 1:10 protease to tagged protein). His6-TEV-
tagged USP1 and His6-TEV protease were bound to Ni-NTA resin,
and cleaved USP1-UAF1 complex was collected in the flow-through.
In order to remove excess USP1, cleaved USP1-UAF1 was then
concentrated and further purified using GL 10/300 Superdex 200
Increase column in 20 mM Tris pH 8.0, 150 mM NaCl, 5% glycerol
and 5 mM DTT. Fractions from the peak containing the protein of
interest were concentrated to ~ 5 mg/ml and cryo-cooled in liquid
nitrogen as single use aliquots. For His6-3C-tagged USP7, protein
was concentrated and subject to two rounds of gel filtration using a
GL 10/300 Superdex 200 Increase column in 20 mM Tris pH 8.0,
150 mM NaCl, 5% glycerol and 5 mM DTT. The centre of the asym-
metric gel filtration peak for USP7 was collected from the first run
and purified again on gel filtration, and the final peak was symmet-
ric and concentrated to ~ 5 mg/ml for flash freezing as single use
aliquots in liquid nitrogen.
GST-USP2 was purified as previously described, and the GST tag
was retained [32]. Protein ubiquitination reagents (Uba1, Ube2T/
Ube2Tv4, FANCL109-375) were prepared as described previously
[26]. Protein concentrations were determined using absorbance at
280 nm and predicted extinction coefficients based on the protein
sequences [39]. The 260/280 ratio of purified proteins measured to
be < 0.8 for all samples, typically 0.6–0.65 suggesting minimal DNA
content.
DNA substrates
IRDye700-labelled dsDNA (ds32F) was obtained from annealing of
two complementary 32 base pair HPLC-purified 50-end IRDye700-
labelled DNA ssDNA molecules. Non-labelled dsDNA (ds32 & ds50)
was obtained from annealing of two PAGE-purified complementary
(32-nucleotide-long or 50-nucleotide-long) ssDNA molecules. The
64-nucleotide-long ssDNA (ss64) was similarly PAGE-purified. The
above dsDNAs were purchased from Integrated DNA Technologies
in their final purified and/or annealed form, were subsequently
resuspended at appropriate stock concentrations in distilled water
and stored at 20°C until use. ssDNA was purchased from Sigma
Aldrich, resuspended at appropriate stock concentrations in 10 mM
Tris pH 8.0, 25 mM NaCl and 0.5 mM EDTA, and stored at 20°C
until use. Sequence details of all oligonucleotides used are provided
in Appendix Table S1.
Assessment of FANCI/FANCD2 ubiquitination or subsequent
deubiquitination by SDS–PAGE, and Coomassie staining or
Western blotting
Non-ubiquitinated/deubiquitinated FANCI or FANCD2 proteins
were distinguished from respective ubiquitinated products/
substrates following SDS–PAGE on Novex 4–12% Tris-glycine gels
(Thermo Fisher) and subsequent staining of the gels with Instant-
Blue Coomassie stain (Expedeon). All samples loaded for SDS–PAGE
(~ 300 ng of FANCD2 for Coomassie staining and ~ 100 ng for
Western blotting) were first diluted with reducing LDS buffer [con-
sisting of NuPAGE 4× LDS buffer (Thermo Fisher) and appropriate
concentration of beta-mercaptoethanol] to 1× LDS and 100 mM
beta-mercaptoethanol or 100 mM DTT final, and then heated for
2 min at 100°C. For assessing the progress of deubiquitination,
ubiquitinated/deubiquitinated FANCI and FANCD2 were addition-
ally visualized by Western blotting. SDS–PAGE-separated proteins
were transferred onto nitrocellulose membranes using an iBlot gel
transfer device (Invitrogen) set at P0 (20 V 1 min, 23 V 4 min, 25 V
2 min) and blocked with 5% milk PBS-T (0.05% Tween 20) before
incubation with 1:1,000 rabbit anti-FANCD2 (sc-28194; Santa Cruz
Biotechnology) and 1:100 mouse anti-FANCI (sc-271316; Santa Cruz
Biotechnology) or anti-V5 (66007.1-Ig; ProteinTech) for 60 min at
room temperature, or overnight at 4°C. Membranes were washed
extensively with PBS-T, incubated with secondary infrared-labelled
antibodies (LI-COR) for 90 min at room temperature and then
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washed extensively again with PBS-T. Bands were visualized on an
Odyssey CLx (LI-COR) using the 700- or 800-nm channel.
Ubiquitination assays
Ubiquitination of isolated FANCI was performed using His6-FANCI
or His6-FANCI
R1285Q (2 lM) as substrate, in the presence or
absence of single-stranded DNA (ss64; 4 lM; Appendix Table S1).
Reactions were conducted using His6-Uba1 (50 nM), His6-ubiquitin
(5 lM), Ube2Tv4 (2 lM) and FANCL109-375 (2 lM) in a final reac-
tion buffer of 49 mM Tris pH 8.0, 120 mM NaCl, 5% glycerol,
1 mM DTT, 2.5 mM MgCl2 and 2.5 mM ATP. Ubiquitination of
ID2 or IR1285QD2 was performed in the presence of double-stranded
DNA (ds50; Appendix Table S1). Reactions were prepared by dilu-
tion of all components into E3 reaction buffer (50 mM Tris pH 8.0,
75 mM NaCl, 5% glycerol, 5 mM MgCl2 and 2.5 mM ATP) to yield
final concentrations of 4 lM FANCI (His6-FANCI or His6-
FANCIR1285Q), 4 lM His6-3C-FANCD2, 16 lM ds50, 4 lM Ube2Tv4,
4 lM FANCL109-375, 100 nM His6-Uba1 and 8 lM ubiquitin. All
reactions were performed at room temperature and stopped at indi-
cated time-points by addition of reducing LDS buffer (1× final
concentration).
Deubiquitination assays
The ID2Ub-DNA and IUbD2Ub-DNA substrates were reconstituted by
mixing appropriate amount of D2Ub, His6-TEV-V5-FANCI or His6-
TEV-V5-IUb and DNA (ds50; Appendix Table S1) to form a I/IUb:
D2Ub:DNA molar ratio of 1:1:4. D2Ub-DNA substrate was prepared
in the same way, but with GF buffer substituting I/IUb. The
substrates were diluted in DUB buffer (50 mM Tris pH 8.0, 75 mM
NaCl, 2 mM DTT, 5% glycerol) on ice to a concentration of 2 lM
and incubated for at least 15 min. USP1-UAF1, USP7 or GST-USP2
were prepared at 2× concentrations in DUB buffer. To initiate reac-
tions, 2× substrate was mixed 1:1 with 2× DUB in a 10 ll reaction
volume and reactions were stopped at indicated time-points by addi-
tion of 10 ll of reducing 2× LDS buffer.
DUB-step assays
His6-TEV-V5-FANCI (4 lM) was ubiquitinated using Ube2Tv4
(4 lM), FANCL109-375 (4 lM), His6-Uba1 (100 nM), wild-type or
mutant ubiquitin (8 lM) and DNA (ds50; 16 lM). All reaction
components (apart from ubiquitin) were first diluted using E3 reac-
tion buffer (50 mM Tris pH 8.0, 75 mM NaCl, 5% glycerol, 5 mM
MgCl2 and 2.5 mM ATP) and reactions subsequently initiated with
addition of ubiquitin at room temperature. Reactions were arrested
at indicated time-points by addition of 5 U/ml apyrase (New
England Biolabs) and subsequent incubation on ice for 5 min. Ubiq-
uitinated FANCI was subsequently mixed in a 1:1 ratio with purified
D2Ub (2 lM ID2, 8 lM DNA) and incubated for a further 15 min on
ice. The reconstituted complexes, D2Ub, IUb-DNA or IUbD2Ub-DNA,
were then subject to deubiquitination by USP1-UAF1 (final concen-
trations 100 nM USP1-UAF1, 1 lM substrate) in 10 ll reaction
volumes for an indicated amount of time at room temperature.
Reactions were stopped by addition of reducing LDS buffer (1× final
concentration). Deubiquitination progress was illustrated with a fit-
ted one-phase decay model (GraphPad Prism).
Electro-mobility shift assays
Indicated FANCI and FANCD2 protein constructs were pooled at
equimolar concentrations and serially diluted in GF buffer. Each
protein dilution was then mixed with EMSA reaction buffer for final
concentrations of 2 nM labelled DNA (ds32F; Appendix Table S1),
16 mM Tris–HCl, pH 8, 150 mM NaCl, 4.4% glycerol, 0.07 mg/ml
BSA, 7 mM DTT, 4 mM EDTA and ID2 concentrations ranging from
4 to 512 nM. For assays testing the effect of salt concentration on
binding, reconstituted ID2 and ID2Ub protein complexes (derived
from His6-TEV-V5-FANCI and either FLAG-FANCD2 or ubiquitinated
FLAG-FANCD2) were diluted in 20 mM Tris pH 8, 200 mM NaCl,
5% glycerol and 7 mM DTT. Each protein dilution was mixed with
EMSA reaction buffer to yield aforementioned final concentrations
but with final NaCl being either 100 mM or 200 mM. Reactions
(18 ll final) occurred on ice for 20 min, before addition of 2 ll of
10× Orange dye. 10 ll was then loaded on 4% polyacrylamide 0.5×
TBE gels, that had been pre-run in 0.5× TBE buffer, and elec-
trophoresis occurred at 135 V for 40–45 min. The gels were subse-
quently scanned in LI-COR imaging system (Odyssey CLx) using the
700-nm laser. Percentage of DNA bound was determined by the
ratio of protein-bound signal to total DNA signal per lane.
Protein induced fluorescence enhancement
For measurement of DNA binding, aliquots of FANCI (His6-FANCI
or His6-TEV-V5-FANCI), FANCD2 (His6-FANCD2 or His6-3C-
FANCD2) or the ubiquitinated versions in GF buffer were thawed on
ice and then mixed at a molar ratio of 1:1 to form each different ID2
complex. Samples were then exchanged into Fluorescence Buffer
(20 mM Tris pH 8.0, 150 mM NaCl, 5% glycerol, 0.47 mg/ml BSA,
1 mM DTT) by fivefold dilution with 20 mM Tris pH 8.0, 87.5 mM
NaCl, 5% glycerol and 0.59 mg/ml BSA. Twofold serial dilutions of
exchanged protein were set up in PCR tubes with Fluorescence Buf-
fer. Labelled DNA (ds32F), which was also diluted into Fluorescence
Buffer, was mixed with each serial protein dilution to yield a final
dsDNA concentration of 125 nM. For measurements testing the
effect of salt, labelled DNA (ds32F) was diluted 200-fold into 20 mM
Tris pH 8.0, 50 mM NaCl, 5% glycerol, 0.47 mg/ml BSA, 1 mM
DTT, or 20 mM Tris pH 8.0, 250 mM NaCl, 5% glycerol, 0.47 mg/
ml BSA, 1 mM DTT, resulting in assay NaCl concentrations of 100
and 200 mM, respectively.
For measurement of FANCI-FANCD2 interaction, aliquots of
FANCD2 (deriving from His6-3C-FANCD2 in which the His6-tag was
cleaved by 3C protease) and His6-FANCI or His6-FANCI R1285Q
were thawed on ice. Samples were then exchanged into Fluores-
cence Buffer by fivefold dilution with 20 mM Tris pH 8.0, 87.5 mM
NaCl, 5% glycerol and 0.59 mg/ml BSA. Twofold serial dilutions of
exchanged FANCD2 were set up in PCR tubes with Fluorescence
Buffer. 120 nM exchanged His6-FANCI was labelled with 50 nM
RED-tris-NTA dye (NanoTemper) in Fluorescence Buffer and added
to the serial dilution to yield a final concentration of 60 nM His6-
FANCI and 25 nM dye.
For measurement of DNA binding of FANCI ubiquitin mutants in
complex with D2Ub, His6-TEV-V5-FANCI was ubiquitinated as per
the DUB-step assays (using a reaction buffer of 10 mM Tris pH 8.5,
75 mM NaCl, 5% glycerol, 2.5 mM MgCl2 and 2.5 mM ATP) and
terminated by addition of 5 U/ml apyrase. 15 ll of this reaction mix
10 of 13 EMBO reports 21: e50133 | 2020 ª 2020 The Authors
EMBO reports Martin L Rennie et al
was added to 5 ll of His6-FANCD2Ub (or GF buffer for the no D2Ub
control) to yield a final concentration of 3 lM IUbD2Ub (or IUb) and a
NaCl concentration of ~ 150 mM. Twofold serial dilutions of this
complex were set up in matched buffer (including all the reaction
components minus ubiquitin), and each was mixed in 1:1 ratio with
labelled DNA (ds32F; 250 nM) in Fluorescence Buffer to yield a final
dsDNA concentration of 125 nM.
Prior to fluorescence measurement, samples were briefly centri-
fuged and then transferred into premium capillaries (NanoTemper
Technologies). Measurements were performed at 22°C on a Mono-
lith NT.115 instrument (NanoTemper Technologies) using the red
channel. Laser power was set to 20 and 40% for DNA binding and
FANCD2 binding, respectively.
Fitting of binding data
Binding affinities and associated uncertainties were determined with
non-linear regression in GraphPad Prism by fitting a one-site bind-
ing model:
Y¼F0þðF1F0Þ
½AT þ½BT þKd
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ð½AT þ½BT þKdÞ24½AT ½BT 
q
2½AT 
where Y is either the fluorescence change (in the case of PIFE) or
the percentage DNA binding (in the case of EMSAs), F0 is baseline,
F1 is the plateau, [AT] is the constant concentration of the fluores-
cent binding molecule, and [BT] is the varying concentration of the
other binding molecule/complex. For EMSAs, the baseline was
constrained to 0 and the plateau was shared between analysed
datasets. For PIFE, fitted curves of Fig 1A were constrained to have
a shared amplitude (F1–F0), which was fixed for fitted curves of
Figs 3E and EV5. Fitted curves of Fig EV1A were constrained to
have a shared amplitude. The baseline was subtracted in the plot-
ted data and curves.
CryoEM sample preparation
FANCD2Ub and His6-TEV-V5-FANCI or His6-TEV-V5-FANCIUb
aliquots were thawed and mixed at a molar ratio of 1:1 and
then exchanged into EM Buffer (20 mM Tris pH 8.0, 100 mM
NaCl, 2 mM DTT) using a ZebaTM Spin 7K MWCO desalting
column. For IUbD2Ub-dsDNA, ds32 (Appendix Table S1) was then
added at a molar ratio of 1:1:1 IUb:D2Ub:DNA. The samples were
diluted to 3 lM (IUbD2Ub-dsDNA) or 1.5 lM (ID2Ub) of complex.
3.5 ll of sample was applied to glow discharged grids (C-Flat
2/2 or Quantifoil 2/2), blotted for 2.5–3.5 s and cryo-cooled in
liquid ethane using a Vitrobot operating at ~ 95% humidity at
4.5°C.
CryoEM data collection and image processing
For IUbD2Ub-dsDNA, 1,846 movies were collected on a Titan Krios
(Thermo Fisher Scientific) equipped with a Falcon III detector
operating in counting mode using EPU software (Thermo Fisher
Scientific). Each movie was 60 frames and motion-corrected with
dose-weighting using MotionCor2-1.1.0. For the ID2Ub sample,
1,146 and 916 movies were collected in two sessions on a
300 kV CRYOARM (JEOL) equipped with a DE64 detector
operating in counting mode using SerialEM [40]. Each movie was
39 frames and additional gain correction applied via relion_esti-
mate_gain. For both datasets, CTF correction was performed
using gCTF [41]. Further data collection details are provided in
Appendix Table S2.
Subsequence processing was performed using RELION 3.0 or 3.1
[42]. For the IUbD2Ub-dsDNA dataset, approximately 5,000 particles
were manually picked and used to generate reference-free 2D class
averages. Selected class averages were then used as templates to
auto-pick particles. 350,878 particles were extracted, and five
rounds of reference-free 2D class averaging were used to remove
poor particles. An initial model was generated using stochastic
gradient descent followed by one round of 3D classification with six
classes. Particles from the highest estimated resolution class
(12,710) were then used in 3D refinement. A mask was then gener-
ated, and post-processing performed. For the ID2Ub dataset particles,
7,810 particles were manually picked, extracted at 4.784 Å/px, and
one round of reference-free 2D classification was performed to
remove poor particles. An initial model was generated using
stochastic gradient descent followed by one round of 3D classifi-
cation with two classes. Particles from the best class (4,404) were
then used in 3D refinement.
The mouse ID2 structure (PDB: 3S4W) [18] was fit as a rigid body
into the final IUbD2Ub-dsDNA map using UCSF Chimera [43]. Flexible
fitting of Ca atoms was subsequently performed using iMODFIT [31]
incorporating secondary structure constraints and using data to
17 Å. The fitted ID2 structure was then used to generate a map at
12 Å, which was subtracted from the experimental map using UCSF
Chimera to identify the difference in density.
Data availability
The data produced in this study are available as follows:
• CryoEM reconstruction (ID2Ub): EMDB EMD-10843 (https://www.
ebi.ac.uk/pdbe/entry/emdb/EMD-10843)
• CryoEM reconstruction (IUbD2Ub-dsDNA): EMDB EMD-10844
(https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-10844)
• PIFE raw and baseline subtracted data: Source Data associated
with this manuscript.
Expanded View for this article is available online.
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